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Abstract 
The Arctic and sub-arctic regions are impacted by the growth of the global 
nanotechnology industry. Nanomaterials have unique chemical and physical properties 
that may lead to toxicological effects that interfere with normal cellular metabolism. Zinc 
oxide nanoparticles (ZnO NPs) are now very common and widely used in daily life. In 
industry, ZnO NPs are used to protect different materials from damage caused by UV
exposure. The scientific literature suggests that ZnO NPs can have negative impacts on
both living organisms and plants. However, there is a paucity of research on the 
mechanisms by which ZnO NPs may affect the neuronal cells. 
This study investigates how ZnO NPs interact with the neuroblastoma cell line 
SH-SY5Y. Using transmission electron microscopy, we observed that the ZnO NPs form 
36 nm particles on average, and increase the level of vascular endothelial growth factor 
(VEGF) in extracellular fluid, as measured by an enzyme-linked immunosorbent assay 
(ELISA). Moreover, ZnO NPs, in presence of tumor neucrosis factor- α (TNF-α), can 
also decrease the level of extracellular VEGF compared with TNF-α treatment alone. 
These findings suggest the basis for more studies on understanding the mechanism by 
which ZnO NPs impact cytokine signaling. Another direction is using ELISA technology 
to observe the interactions of NPs with different cell types such as neuronal stem cells.
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Chapter 1: Background and Introduction 
1.1 Nanoparticles and Zinc Oxide 
Nanoparticles (NPs) are particles with a diameter typically smaller than 100 
nanometers (nm) that differ from their bulk form (diameter >1000nm) and usually have 
unique properties. Carbon nanotubes are one of the most widely used nanomaterials. 
These NPs conduct heat efficiently and have unique electrical properties, as well as 
distinctive architectures. They are usually composed of many nanotubes bonded together 
and possess a highly activated surface. Hydroxyapatitie (HA) and carbon-coated titanium 
alloys are other examples of commonly used NPs. They have been used in bone and hip 
replacements in the medical field (Yang et al., 2010). NPs are also used in the 
pharmaceutical field to develop substances for drug delivery (De Jong and Borm, 2008). 
This is especially true for the anticancer, anti-bacterial and anti-viral drug development 
industries. Nowadays, researchers find that NPs can be applied to cell-specific targeting 
of Leukemia and other cancer types and, increasing the diversity of the biotech industry. 
Although nanomaterials bring benefits, they also can have negative impacts on the 
ecosystem and living organisms. The disposing of carbon nanotube batteries can be a 
problem. If they are not disposed properly, they can move into the ecosystem; be 
accessed by some living organisms, including humans, via the food chain; and potentially 
lead to cancer (Buzea et al., 2007). Also, the NPs’ unique surface properties (i.e. the 
charge and the reactivity) can lead to unexpected biological inflammations. Since NPs 
can pass the blood brain barrier based on their small size (De Jong and Borm, 2008), they 
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have access to neurons. Several toxicological studies support the contention that airborne 
NPs and are correlated with inflammatory effects (De Jong and Borm, 2008, 
Dobrovolskaia et al., 2008, Borm et al., 2006). 
ZnO NPs, as one of the common metal nanomaterials, have been used in common 
products. In the construction industry, ZnO NPs are used to coat wood, plastic or textiles 
to protect them from exposure to UV light. In the cosmetic field, ZnO NPs are an 
essential element in sunscreens. Although ZnO NPs have enjoyed a good reputation for 
their diverse properties, they are rarely studied for their toxicity. Kumari and his team 
have found that ZnO NPs can act as clastogenic and cytotoxic agents when NPs contact 
with root cells of Allium cepa (Kumari et al., 2011). NPs have been found to be toxic not 
only in plants cells, but also in animals. Bai et al. (2010) found that ZnO NPs are toxic to 
the zebrafish embryos. Specifically, the research found that 30 nm nanoparticles form 
aggregates of different sizes during the exposure process. They showed that the exposure 
to ZnO NPs induced embryonic mortalities, though, the exposure did not lead to direct 
embryonic death. In addition, the high concentration of ZnO NPs and the Zinc ions 
decreased the embryos’ hatching rate. Exposure to ZnO NPs also shortened the body 
length of larvae and induced tail malformation as the concentration increased (Bai et al., 
2010). 
3 
1.2 Cytokines 
Cytokines are a group of proteins that play an important role in cell signaling. 
They are secreted by numerous cells, and in particular, immune cells. Upon cell 
stimulation, some cytokines increase up to 1000-fold in plasma after trauma or infection, 
and sometimes they are used as biomarkers by clinicians to monitor for infection and 
inflammation (Hopkins et al., 2012, Kemp et al., 2005, Fava et al., 1994). 
Cytokines, such as Interlukin-1 (IL-1) and Tumor Necrosis Factor-α (TNF-α), are 
involved in the immune response to infection in abnormal cells, and are characterized as 
pro-inflammatory (Boyle 2005). Production of the pro-inflammatory cytokines has been 
associated with tumor growth in a variety of neoplasms and neurological disorders (Duffy 
et al., 2011). The IL-1 family also is important in both acute and chronic inflammation. 
IL-1 receptor binding induces the activation of transcription factors and the expression of 
genes that promote the production of other cytokines as well as growth factors, such as 
vascular endothelial growth factor (VEGF) (Duffy et al., 2011). Two forms of IL-1 exist 
(IL-1α and IL-1β), which interact with the type I and type II IL-1 receptors. IL-1 binds to 
the receptor type I and initiates a signaling cascade leading to the activation of the 
transcription factor, nuclear factor-κB, which is central to inflammatory and immune 
responses, as well as angiogenesis (Monaco et al., 2004). 
VEGF, as mentioned earlier, can be induced by IL-1 during the inflammation. It is 
also known as vascular permeability factor (VPF) or vasculotropin. VEGF is expressed 
by numerous rodent and human tumor cells (Kemp et al., 2005). In normal tissue, VEGF 
expression has been found in activated macrophages (Fava et al., 1994); keratinocyte 
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(Brown et al., 1992b); renal glomerular visceral epithelium and mesangial cells (Brown et 
al., 1992a, Iijima et al., 1993); hepatocytes (Monacci et al., 1993); smooth muscle cells 
(Ferrara et al., 1991); embryonic fibroblasts, bronchial, choroid plexus epithelia cells 
(Pertovaara et al., 1994, Breier et al., 1992) as well as neurons and glial cells 
(Storkebaum and Carmeliet, 2004). 
The occurrence of VEGF/PlGF heterodimers has also been observed in the 
conditioned media of human choriocarcinoma cells (JAR
*
 and JE-3
†
)
 
(Cao et al., 1996),
in which PlGF, a protein called placenta growth factor, is one that activates growth 
factors (Roskoski 2007). In vivo, VEGF can induce angiogenesis, a process that is 
associated with wound healing, embryonic development, and the growth and metastasis 
of solid tumors, as well as an increase in microvascular permeability (Kemp et al., 2005). 
Based on all the factors listed above, VEGF is expected to play an important role in 
inflammation during pathological angiogenesis. Elevated levels of VEGF have been 
reported in synovial fluids of rheumatoid arthritis patients and in sera from cancer 
patients (Koch et al., 1994, Senger et al., 1993, Kondo et al., 1994). 
*
 JAR: Experimental cell line 
††
 JE-3: Experimental cell line 
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1.3 Flow Cytometry 
Flow Cytometry technique was developed during 1970s by a research group at 
Stanford University and was patented as the first Fluorescence Active Cell Sorter (FACS). 
In 1974, the first commercial flow cytometer called the FACS-1 was licensed by Becton 
Dickinson, Inc. During the late 1970’s, multi-parameter capability for flow cytometers 
was developed. During the early 1980’s, the first high-speed flow cytometer was 
successfully used to sort human chromosomes as part of the Human Genome Project. By 
the end of the 1980’s, flow cytometers became the industry-standard commercial cell 
analyzer (Herzenberg et al., 2002). Nowadays, flow cytometers are employed in various 
fields, such as academic research, commercial research and clinical diagnoses. 
I collaborated with Dr. Dunlap’s research group to develop the flow cytometry 
method to monitor cell populations after treatments involving exercise. Our initial effort 
was focused on the influence of exercise on measuring the expression of GLUT4 
receptors on the membrane of white blood cell populations in sled dogs. 
It is intended that this technique will eventually be used to monitor the changes in 
neuroblastoma and stem cells after exposure to ZnO NPs and other nanoparticles. 
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1.4 Significance and Research Hypothesis 
1.4.1 Significance  
The production of engineered nanomaterials in 2004 was 2000 tons and is 
projected to increase to 58,000 tons by 2020 (Nowack and Bucheli, 2007). However, the 
unique properties of metal oxide nanomaterials may have a negative impact on the 
ecosystem.  
In this research, we focused on the ZnO NPs because they have been widely used 
in consumer products such as sunscreens. Kumari (Kumari et al., 2011) and his team 
reported that ZnO NPs can act as both clastogenic and cytotoxic agents when in contact 
with root cells of Allium cepa (onion bulb). They compared ZnO NPs (size < 100 nm 
with varying concentrations) with ZnO bulk (size < 5µm with different concentrations) 
forms. The ZnO NPs increased lipid peroxidation in A. cepa cells. Bai and his group 
observed ZnO NPs were also toxic to the zebrafish embryos, exposure to 50 and 100 
mg/L ZnO NPs increased the embryonic mortalities, shortened the body length of larvae, 
and induced tail malformation when the concentration reached 10 mg/L (Bai et al., 2010). 
Using these studies as an indicator, it is obvious that researchers should expand studies 
on the mechanism of ZnO NPs on cell signaling. Our research is an attempt to build a cell 
culture model that allows for the study of cell-signaling after exposure to NPs as well as 
facilitate the potential of development of neuro-protective nutraceuticals that can reduce 
the impact of ZnO NPs exposure.  
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1.4.2 Research Hypothesis 
At the outset of this research, our goals were relatively broad and exploratory in 
nature. My literature research found no reported studies of NPs effect on SH-SY5Y cells, 
so as an exploratory study. There are few studies where metallic nanomaterilas have been 
used to investigate toxicology at the cellular level. Among these few studies, they only 
reported mortality effect the cells in culture. This exploratory study is the first, to our 
knowledge, to access the impact of metallic nanomaterials on cytokines like VEGF. For 
this exploratory research, initial hypotheses were developed, and modified as exploratory 
results were obtained. Theses hypothesis are: 
1. ZnO NPs have a relatively stable size and structure in solution  
2. ZnO would not significantly impact the pH of the cell media  
3. ZnO NPs are toxic to SH-SY5Y cells alone at defined concentrations (5µl/ml to 
10µl/ml) 
4. The toxicity of the ZnO NPs can be correlated with the release of extracellular 
VEGF by SH-SY5Y 
5. ZnO NPs will inhibit the effect of TNF-α on SH-SY5Y cells as judged by the 
release of VEGF into culture media 
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Chapter 2: Materials and Method 
2.1 Human SH-SY5Y Cell Culture  
 Human SH-SY5Y neuroblastoma cells were grown from the frozen cells, stored 
in liquid nitrogen, then thawed in to 100-mm dishes (Falcon) containing: high-glucose 
DMEM (pH 7.4), 10% fetal bovine serum (FBS), 3.7 g/L sodium bicarbonate, 100U/ml 
of penicillin and streptomycin, and 1% GlutaMax-1 (GM) (Table 2.1). Cultures were 
incubated in a humidified atmosphere with 5% CO2 at 37ᴼC. After one week of 
incubation, cells were detached using 0.5 mg/ml trypsin (5 min, 37ᴼC), collected by 
centrifugation (1,200 rpm), and plated into six-well plates. After another week of 
incubation in the six-well plates, the media was replaced with serum-free media. All 
experiments were carried out 24-hours after serum depriving the neuron cultures.  
Table 2.1 Sources of materials used  
BCA Protein assay kit Pierce Biotech  
DMEM powder Mediatech 
Fetal Bovine Serum Atlanta Biologicals 
GlutaMax-1 Invitrogen  
Human SH-SY5Y neuroblastoma cell ATCC 
Human VEGF assay kit R&D Systems 
IL-1 assay Kit R&D Systems 
Trypsin Invitrogen 
TNF-α assay kit  R&D 
SystemsParaformaldehyde Invitrogen 
Penicillin/Streptomycin Mediatech 
Recombinant human TNF-α ProSpec 
RPMI media  Invitrogen 
Zinc Oxide nanoparticles (ZnO NPs), 36 nanometer, powder Alfa Aesar  
All other reagents Sigma-Aldrich  
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2.1.1 Light Microscopy of SH-SY5Y Cell  
 After growing for one week in a six-well plate, neuroblastoma cells were 
observed under the Nikon Eclipse TE 2000U inverted microscope to assess the normal 
condition of the cells. Morphology changes after the treatments were noted. Normal 
morphology shows asymmetric cells with processes.  
2.1.2 pH Detection in Human SH-SY5Y Cell Media 
pH is an important parameter that can alter the cell’s viability. Proteins, nucleic 
acid and lipids need to maintain the interval pH for their normal function such as signal 
transduction, gene expression and membrane physiology. Changes in hydrogen ion 
concentrations can impact normal cells’ metabolism. pH was measured using the Thermo 
Orion 420 Plus pH meter after treatments and as well as the blank. 
2.2 Human SH-SY5Y Cell Treatments  
 Cell cultures in six-well plates that were free of microbial contamination were 
deprived of serum for 24h. The cell cultures were then treated with the following: a) a 
controlled culture with no treatment, b) a culture with 0.2 µg/ml of ZnO NPs for 4h, c) a 
culture with 0.4 µg/ml of ZnO NPs for 4h, d) a culture with 0.125 µg/ml TNF-α for 4h, e) 
a culture with 0.125 µg/ml TNF-α for 30 minutes, and f) a culture with 0.4 µg/ml of ZnO 
NPs for 4 hours, followed by addition of 0.125 µg/ml TNF-α for 30 minutes. The 6-well 
plates were incubated in a humidified atmosphere of 5% CO2 at 37 ᴼC for either 30 
minutes or 4 hours. 
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2.3 Transmission Electron Microscopy 
 Transmission Electron Microscopy (TEM, JEOL 1200) was used to detect the 
morphology characteristics of ZnO NPs. ZnO NPs were dispersed in propylene glycol 
(PG) in a 1:9 PG ratio (10µl of NPs and 90µl PG) for a 10% final solution. 5µl of 
prepared ZnO NPs solutions were pipetted on to the TEM grid and after 20s, were blotted 
off the grid, then 5µl of DI water was placed on the grid for 20s and blotted from the grid. 
After repeating 3 times, the grid was dried overnight. The grid of ZnO NPs was examined 
after one day. 
2.4 Enzyme-linked Immunosorbent Assay 
 Enzyme-linked immunosorbent assay (ELISA) is a very powerful biological 
technique that uses antibody and color change to quantify the substance of interest.  
The principle for these assays, in general, is that antibodies can specifically bind with 
certain substances (antigens or hapten). There is a microplate (usually a 96-well plate) 
which is pre-coated with known antibody specific to the protein of interest. When 
standards and samples are added into the wells, the substance (antigen or hapten) will 
bind to the immobilized antibody. Then a secondary antibody with an attached enzyme 
added to each well; this antibody binds with the antigen. The attached enzyme is reacts 
with an added secondary substrate, which will finally develop a color change and the data 
can be detected by an absorbance plate reader. The substance (antigen or hapten) in the 
samples can be detected both qualitatively and quantitatively. 
 For VEGF, as a specific example, a monoclonal antibody specific for VEGF has 
been pre-coated onto a microplate. If VEGF exists in the samples, it will bind to the 
12 
immobilized antibody. After 3 repeated, saline washes steps to clear away the unspecific 
binding, an enzyme-linked polyclonal antibody specific for VEGF is added to the wells. 
A substrate solution is added after, and then the color develops in proportion to the 
amount of VEGF in the samples. Final measurements are done by using a plate reader set 
for λ=450 nm. The concentration of VEGF in the sample is determined by interpolation 
from a standard curve. The same basic principle and approach is applied in IL-1α assay 
(Duffy et al., 2011, Kemp et al., 2005). 
2.4.1 BCA Protein Assay 
 The BCA protein assay (Pierce) is commonly used to determine protein content in 
samples. It is a detergent compatible formulation based on bicinchoninic acid for the 
colorimetric detection and quantitation for total protein in the samples. The assay is based 
on the principle that Cu
2+
 is reduced to Cu
+
 by protein in an alkaline medium, which is 
called the biuret reaction. The reaction is detected with a highly-sensitive and selective 
colorimetric detection of the Cu
+
 using a unique reagent containing bicinchoninic acid. 
The final color of the solution will be purple and depends on the concentration of proteins 
existing in samples. The colors can also appear in different shades. The purple color is 
caused by the chelation of two molecules of bicinchoninic with one Cu
+
. 
2.4.2 VEGF Assay  
 The human R and D system VEGF ELISA assay allows measurements of extra 
and intracellular VEGF from cultured human SH-SY5Y cells. By following published 
directions (R&D Systems), VEGF was detected in a colorimetric change plate. A 
Beckman-Coulter Multimode DTX 880 multi-plate reader detected the color change at an 
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absorbance λ=450nm. For this assay, the lowest detectable concentration of VEGF is 5.0 
pg/ml. 
 After ZnO NPs and TNF-α treatments, the media was directly removed and 
utilized for the extracellular assay. The same remaining cells were rinsed with PBS. Cells 
were removed by scraping in ice-cold PBS. The cells were collected in Eppendorf tubes 
and sonicated for 5 seconds then utilized for the intracellular assay. 
2.4.3 IL-1α Assay 
 The human R and D system IL-1α assay allows measurements of extracellular and 
intracellular IL-1α from human SH-SY5Y cells. A Beckman-Coulter Multimode DTX 
880 multi-plate reader detected the color change at an absorbance λ=450nm. 
 IL-1α levels were determined for both secreted (extracellular) and cellular 
(intracellular) concentrations in SH-SY5Y cells after ZnO NPs and TNF-α treatments. 
The media was directly removed and added to the ELISA plate to detect the extracellular 
IL-1 level. The same remaining cells were rinsed with PBS. Cells were removed by 
scraping in ice-cold PBS. The cells were collected in Eppendorf tubes and sonicated for 5 
seconds and utilized for the intracellular assay.  
2.5 Flow Cytometry  
Flow cytometry is a laser-based, biophysical technology employed in cell 
counting, sorting and biomarker detection. This technique has been commonly used to 
diagnose health disorders, especially hematological diseases. The principle of sorting 
particles is based on their different chemical and physical properties. The specific cell 
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populations can be tagged with specific fluorescent markers in order to separate them 
from other populations.  
In the project, I used FITC that was conjugated to the secondary antibody, in 
order to target the GLUT4 receptors on the cell membrane and detect the florescent signal 
by using flow cytometry. The results will show us if there will be different expression 
levels of GLUT4 receptors on mononuclear cells’ membrane from sled dogs measured 
before exercise, immediately after exercise, and after a recovery period of 24 hours. This 
research will contribute to develop an improved way to detect blood GLUT4 levels as 
well as contribute to the development of a low-invasive diagnostic tool for insulin 
resistance and type II diabetes.  
15 
Chapter 3: Results 
3.1 Characteristics of Zinc Oxide Nanoparticles 
 The characterization of ZnO NPs was critical at the outset of this research. The 
size and shape of the ZnO NPs was detected and observed using TEM machine at several 
magnifications. One result shows that ZnO NPs tended to form aggregates in aqueous 
environments under 100,000 magnification, which is consistent with other ZnO NPs 
morphology studies (Figure 3.1).  
 
Figure 3.1 ZnO NPs morphology under 100,000X 
 The ZnO NPs tended to form aggregates; but most individual particle’s size is still 
smaller than 100nm. Figure 3.2 suggests that any effects of ZnO to cell cultures will be 
caused by its “Nano” form, not its “Fine” form in which particle diameters is between 
100nm and 1000nm, or its “Bulk” form in which particle diameter is larger than 1000nm. 
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Figure 3.2 ZnO NPs morphology under 300,000X 
 Figure 3.3 shows the general morphology of ZnO NPs under the 500,000 
magnification. ZnO NPs do not show a clearly-defined shape. They can be observed as 
three types: oval shape, rectangular-elongated shape and round shape. The darker color of 
ZnO NPs in Figure 3.3 indicated that ZnO NPs are overlapping each other. When 
magnification was expanded, the definition of these elongated ZnO NPs was more 
evident and the average size was estimated to be 36nm.  
 The particles exist within a narrow range size. Generally speaking, individual 
particle diameter is smaller than 100nm and particles tend to aggregate in aqueous 
environment. All these characteristics can be important for their interactions with SH-
SY5Y cells. 
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Figure 3.3 ZnO NPs morphology under 500,000X 
3.2 Acid-Base Cell Culture Environment  
 The hydrogen ion concentration (pH) is an important cell culture parameter that 
can alter the cells’ viability. Altering the pH of cell media (living environment) can alter 
the behavior of proteins, nucleic acid, lipids and other important molecules’ normal 
function. Maintaining pH in a defined range is required for cells to perform their normal 
metabolic activity.  
 ZnO is known to be an amphoteric oxide, whether the cell media pH was changed 
after the addition of the ZnO NPs was recorded by using a Thermo Orion 420 Plus pH 
meter (Table 3.1).
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Table 3.1 pH changes of cell culture media after treatments 
Sample 
Concentration 
(ZnO NPs/TNF-α) 
pH 
Difference 
between no 
treatment and 
treatments 
No Treatment 0.00 µg/ml 6.94 ——— 
ZnO NPs 0.20 µg/ml 6.99 0.05 
ZnO NPs 0.40 µg/ml 7.01 0.07 
ZnO NPs 0.80 µg/ml 7.07 0.13 
TNF-α 0.125 µg/ml 7.19 0.25 
 We compared the difference in pH for at the listed concentrations (Table 3.1) of 
ZnO NPs and TNF-α treatments used in these experiments with no treatment, the average 
difference in pH between ZnO NPs treatments and no treatment is 0.08. The TNF-α, is 
used throughout the study, because it shows a positive release of VEGF into the media, 
also had an impact on the pH on the media. The difference between TNF-α treatment and 
no treatment was 0.25. 
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3.3 Cell Viability 
3.3.1 Light Microscopy of Human SH-SY5Y Cell 
 The standard shape of SH-SY5Y cells in culture is well-defined (Gustafson et al., 
2012). The morphology of SH-SY5Y cells under 20X magnification after 24h (in a 
serum-free media) demonstrates that the cells remain healthy. The cells maintain their 
projections and shape. This illustrates the nomal morphology of the cells before 
treatments in a serum-free media (Fig 3.4).  
 
Figure 3.4 SH-SY5Y in serum free cell culture 
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3.3.2 Impact of ZnO NPs on SH-SY5Y Cell 
 Our results showed that high concentration of ZnO NPs, which is 0.80 µg/ml 
(equals 20µl added to cell media) over 24 hours resulted in the complete mortality of the 
cells. A series of concentration and time-dependent experiments were used to define 
conditions for observing impacts of low concentrations of ZnO NPs. 
Figure 3.5 shows the morphology of SH-SY5Y under 20X after 1 hour of 0.4 
µg/ml ZnO NPs treatment. The morphology changed distinctly. The numbers of axon 
projection were reduced, and many cells changed morphology to a rounded shape. 
 
 
Figure 3.5 SH-SY5Y in ZnO NPs exposure (1h) 
After 4h, the morphology of SH-SY5Y of 0.40 µg/ml ZnO NPs treatment showed 
that most cells lost their normal morphology and axon projections. There was almost 
complete disappearance of connectivity between cells (Fig 3.6). 
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Figure 3.6 SH-SY5Y cell culture in ZnO NPs exposure (4h) 
3.4 ZnO NPs and VEGF Secretion 
As mentioned in the hypothesis section, we expected to see that ZnO NPs 
treatments cause an increased release of extracellular VEGF. The results of the ELISA 
assay for VEGF support this hypothesis.  
The results showed that 0.4 µg/ml of ZnO NPs a for 4h exposure treatment 
increased the extracellular VEGF concentration. However, the VEGF level in ZnO NPs 
treatment was less than the TNF-α treatment under the same time period exposure. The 
ZnO NPs treatment showed 160 pg/ml VEGF while TNF-α showed 450 pg/ml. 
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Figure 3.7 VEGF extracellular releases after TNF- α 
Figure 3.7 shows that, after different incubation times with 0.125 µg/ml of TNF-α, 
the level of VEGF extracellular release is different depending on length of the exposure. 
The level of VEGF in the media after a 4h incubation is almost two times that of the 
sample after a 30-minute incubation. This is expected because the longer the exposure 
time the more the VEGF will be released into the culture. This data shows that VEGF 
release under the TNF-α stimulation is a time-dependent behavior, the longer the 
exposure time, the more VEGF been induced. This data also shows the responsiveness of 
the cells. TNF-α is a positive control in our treatment. These results are also consistent 
with previously reported results, for a 30-minute TNF-α incubation that can increase the 
extracellular VEGF level (Duffy et al., 2011). The VEGF level in the sample without 
TNF-α treatment was under the detectable level. Since this is only one trail ran in 
triplicates, statistics were not performed, although this explored the issue of whether 
exposure length could impact VEGF levels in future studies. 
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Figure 3.8 VEGF extracellular releases after combining TNF-α and ZnO NPs 
Figure 3.8 shows extracellular VEGF concentration after treatment of ZnO NPs 
(0.4 µg/ml) followed by a 30-minute TNF-α (0.125 µg/ml) treatment. The 30-minute 
TNF-α (0.125 µg/ml) treatment is shown as a baseline stimulation. This result showed 
that the level of VEGF release after TNF-α (0.125 µg/ml) treatment is higher than in ZnO 
NPs (0.4 µg/ml) for 4h and followed by a 30-minute TNF-α (0.125 µg/ml) treatment. An 
explaination for this result is that ZnO NPs supressed the level of TNF-α induced VEGF 
release. An alternative explanation is that ZnO NPs killed the cells, reducing the number 
of cells that can release VEGF. The second explanation is supported by the light 
microscopy result shown in Fig 3.6, in which there is a decreased number of cells in the 
two ZnO NPs treat wells (Table 3.2). This can be interpreted that ZnO NPs killed cells so 
they could not emit VEGF. The reduced amount of protein detected by the BCA protein 
assay indicated the reduced number of cells. Since only duplicates performed in the 
experiment, these results are not significant and should be verified by repeated trails in 
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the future. Repeated trails will also allow us to address the significance of the difference 
in protein levels between longer and shorter ZnO NPs exposure periods. 
The effects of stressors, either cytokines or toxicants, can be additive, subtractive 
or synergistic. Figure 3.8 show that in the effect of ZnO NPs+TNF-α appears subtractive. 
Table 3.2 BCA protein assay  
samples  No Treatment ZnO 
0.4 µg/ml 
(30min) 
ZnO 
0.4 µg/ml 
(4h) 
TNF-α  
0.125 µg/ml 
(30min) 
1 0.085 0.061 0.075 0.096 
2 0.097 0.060 0.067 0.083 
AVE 0.090 0.061 0.071 0.090 
 
 
Figure 3.9 VEGF extracellular releases after combining ZnO NPs and TNF-α 
blank showed under detectable level of VEGF 
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Figure 3.9 shows that after 4h treatment with ZnO NPs (0.4 µg/ml) alone and with 
TNF-α (0.125 µg/ml, 30 minutes after 4h ZnO NPs treatment), there was no difference in 
extracellular VEGF. This result shows that pretreatment of ZnO NPs does not directly 
enhance the TNF-α induction of VEGF, and may inhibit it.  
3.5 ZnO NPs affects IL-1α  
Interleukins are a large group of proteins produced mainly by T-cells and in some 
cases by mononuclear phagocytes. Most interleukins direct other cells to divide and 
differentiate. Interleukins largely participate in the regulation of immune response, as 
well as inflammation and hematopoiesis. Each acts on a specific group of cells that have 
receptors specific to an interleukin. 
IL-1 is a name and designation for two proteins, IL-1α and IL-1β, which are the 
products of distinct genes. Both of these proteins recognize the same cell surface 
receptors. IL-1 is usually not produced by healthy individuals, except in skin 
keratinocytes, some epithelial cells, and certain cells in the central nervous system 
(Dinarello and Wolff, 1993). A dramatic increase in the production of IL-1 is commonly 
detected after stimulation by inflammatory agents or microbial endotoxin. In this project, 
IL-1 was also investigated, however, there was no difference between the control and 
ZnO NPs’ treatment. All but the TNF-α control sample were below detectable levels. 
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Chapter 4: Discussion and Future Directions 
ZnO NPs have been used in many products. Previous studies (Bai et al., 2010) 
show that the aggregation effects can increase the toxicity of ZnO NPs. TEM results in 
this research show that ZnO NPs (size=36nm, 4% in PG) aggregate in solution and the 
average size of the particles is about 36nm. Moreover, these particles do not have a 
definite shape and therefore they can potentially affect cells differently. However, there is 
no reported research on neuronal cells and cytokines are usually not studied. Some 
researchers revealed that nanoparticles could be shaped to fit to particular proteins, and 
have important interactions with complement proteins (Dobrovolskaia et al., 2008). In 
addition, researchers shows that the smaller the size of nanoparticles, the more toxic they 
are (Kumari et al., 2011, Bruneau et al., 2013). 
TNF-α and IL-1 have primary roles in the regulation of immune cells through NF-
κB signaling pathway, and contribute to the adaptive immunity and secretions of pro-
inflammatory cytokines (Janeway et al., 1999). VEGF is a signal protein that is produced 
by numerous types of cells. VEGF can stimulate new blood vessels and lymphatic vessels 
to grow under normal conditions. When VEGF is over-expressed, it can contribute to 
diseases, especially cancer. In advanced cancer studies, researchers create VEGF-
receptors antagonists to block the VEGF production in tumor cells. This is under 
development as a potential cancer therapy (Kerbel, 2000). 
Our research reveals that after 4h incubations with ZnO NPs, the normal 
morphology of SH-SY5Ycells disappear. They lose their projections of axons and the 
interactions with nearby cells. The ELISA results show that ZnO NPs with a 
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concentration of 0.4 μg/ml increased the extracellular VEGF production by about 160 
pg/ml after 4h incubation. On the same plate, the VEGF in the blank (no treatment) was 
below the detectable limits (5 pg/ml). In comparison, using exposure to TNF-α with a 
concentration of 0.125 μg/ml, which increased the extracellular VEGF production by 
about 450 pg/ml after 4h incubation with the ZnO NPs, has a lesser effect on extracellular 
VEGF production compared with TNF-α treatments alone. In addition, we studied the 
double-effects of ZnO NPs and TNF-α to SH-SY5Y cells. The results show that the 
extracellular VEGF production is almost the same under ZnO NPs and ZnO NPs+TNF-α 
conditions. And the ZnO NPs+TNF-α treatment has fewer effects on extracellular VEGF 
production (160 pg/ml) than the TNF-α treatment alone (450 pg/ml). This result has two 
possible explanations: 1) the ZnO NPs can inhibit the releasing of VEGF in the presence 
of TNF-α, which can be used in a potential cancer drug development, or 2) the ZnO NPs 
killed the cells before they could release more VEGF into media. The second explanation 
is supported by both the image result (Fig 3.6) and BCA protein result (Table 3.2). In 
addition, the results from the ELISA also show that the effects of ZnO NPs on the SH-
SY5Y cells may also be through the pathway leading to VEGF secretion. The ZnO NPs 
do not induce the releasing of IL-1α according to this research.  
Figure 4.1 shows a schematic diagram summarizing the results from the ELISA, 
and suggesting the ZnO NPs may interfere with the TNF-α regulating pathway. This 
interference leads to reduction in the TNF-α-stimulated release of VEGF. 
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Figure 4.1 Diagram shows the pathway involved in ZnO NPs, VEGF and TNF-α 
This research is in the preliminary stage of developing a model system. Future 
experiments will be required to better understand what effects ZnO NPs have on neuronal 
cells. I suggested the following studies to be conducted 
1) The permeability of ZnO NPs through biological membranes 
2) The aggregation effect of ZnO NPs on cells 
3) Whether ZnO NPs will affect the release of other cytokines such as IL-4 and 
IL-10, inhibitory cytokines that are capable of inhibiting synthesis of pro-inflammatory 
cytokine such as TNF-α. 
There are many questions that need to be answered about characterization of ZnO 
NPs and neuronal cells. Answering these questions will be crucial to regulating the fast 
growing nanotechnology industry. 
As described in Appendix B, another future direction of this project will be the 
use of flow cytometry to sort different populations of cells and study the ZnO NPs’ 
effects on the cell viability and molecular expression in immune cells. 
The research in this thesis was exploratory in nature. We performed numerous 
experimental trials, some of which did not work as expected, and through this 
experimentation, we discovered how to improve the design and what were key factors 
(+) 
(+) 
ZnO NPs 
VEGF TNF-α 
(-) 
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and components to pay attention to. Since many of these tests were only performed in one 
or two trials, we did not perform standard statistical analyses of the results. Future work 
would include more trials so as to demonstrate the statistical significance of the results. 
This exploratory research gave us preliminary results that help us to design cell culture 
experiments to understand the effect of ZnO NPs exposure on VEGF secretion in SH-
SY5Y cells. 
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Appendix A Supplementary Data 
Table A.1 Corresponds to Figure 3.7 
VEGF 
(pg/ml) 
TNF-α 
0.125 µg/ml 
(30min) 
TNF-α 
0.125 µg/ml 
(4h) 
R1 202.53 481.35 
R2 204.00 427.12 
R3 217.58 461.58 
AVE (n=3) 208.04 456.68 
SD (+/-) 4.79 15.85 
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Table A.2 Corresponds to Figure 3.8 
VEGF 
(pg/ml) 
TNF-α 
0.125 µg/ml 
(30min) 
ZnO NP 0.4 µg/ml (4h) 
TNF-α 0.125 µl/ml (30min) 
R1 202.54 174.65 
R2 204.00 160.12 
R3 217.58 154.50 
AVE (n=3) 208.04 163.09 
SD (+/-) 4.79 6.01 
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Table A.3 Corresponds to Figure 3.9 
VEGF 
(pg/ml) 
ZnO NPs 
0.4 µg/ml (4h) 
ZnO NP 
0.4 µg/ml (4h) 
TNF-α 
0.125 µg/ml (30min) 
R1 162.92 174.65 
R2 161.77 160.12 
R3 161.92 154.50 
AVE (n=3) 162.21 163.09 
SD (+/-) 0.36 6.01 
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Appendix B Developing Flow Cytometry on Cells 
Demonstration of Different Cell Populations in Sled Dogs Mononuclear cells 
 Flow Cytometry is a very powerful tool for researchers to study different cell 
populations. In order to sort out different populations in Flow Cytometry, researchers 
usually tag fluorochromes on antibodies. In this study, the antibody has been conjugated 
with the fluorochrome, FITC. Fluorescein isothiocyanate (FITC) is a derivative of 
fluorescein. It has excitation and emission spectrum peak wavelengths of approximately 
495 nm/519nm which shows in the range of green color (Fluorophores.org). 
 In this particular project, we are interested in studying the effects of exercise on 
GLUT4 receptor expression levels on white blood cell membranes. GLUT4 (glucose 
transporter type 4) is the insulin-regulated glucose transporter. It exists abundantly in 
adipose tissues, and skeletal and cardiac muscle. The fat cells and muscle are two major 
tissues in the body that respond to insulin. Studying the impact of exercise on expression 
levels of GLUT4 is crucial to obtain a better knowledge of Type 2 Diabetes (insulin 
resistant diabetes). 
 Sled dogs are the model animal for this study. We monitored three different 
conditions of the dogs’ mononuclear cells samples: 
1. Sled dogs before exercise, pre 
2. Sled dogs after exercise, t=0 
3. Sled dogs 24 hours after exercise, t=24h 
 8 dogs were used for the 3 different conditions (for each condition, n=8), and their 
mononuclear cells samples were monitored under the flow cytometer after each condition.  
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Methods 
Fixation  
1. Collect cells by centrifuge (at the speed of 3600 RPM/1500g) and aspirate 
supernatant 
2. Re-suspend cells in 3ml of 2% paraformaldehyde in PBS 
3. Fix for 10min at 37ᴼC 
Staining 
1. Block in 2-3ml of incubation buffer (dissolve 0.5g bocine serum albumin in 
100ml 1X PBS) for 10 min at RT  
2. Centrifuge and re-suspend in primary antibody (5μg/ml in 3% BSA/PBS) 
3. Incubate 30 min at RT 
4. Rinse with 2 ml/sample incubation buffer by centrifuge at 300 RCF for 15 min 
5. Re-suspend cells in flurochrome-conjugated secondary antibody diluted in 
incubation buffer (1:200 dilution in 3% BSA/PBS)  
6. Incubate for 30 min at RT 
7. Rise with incubation buffer 
8. Re-suspend cells in 3ml/sample 1% BSA/PBS  
9. Aliquot 1ml of sample into Eppendorf vials 
10. Analyze on flow cytometer 
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Results 
 
Figure B.1 Dot plot for Rossi pre-exercise 
 
Figure B.2 Experiment data corresponds to Figure B.1 
In Figure B.1, the X-axis (FSC-A) represents the overall size of the individual cell, 
the Y-axis (SSC-A) represents the complexity or the granularity of the cells. From the dot 
plot, the data shows that there are three different populations in the Rossi pre-exercise 
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white blood samples, and similar results are also found in the other 7 dogs. The 3 
different populations were grouped based on their different sizes and granularity. P3 
(showns in green) has the smallest size and the least complexity among all the 3 
populations. P2 (showns in blue) has the biggest size and the most complexity among all 
the 3 populations. At this early stage, our prediciton on these three populations will be: 
P1 is the monocyte, P3 is the lymphocyte. However, furture experiment is needed to 
verify these populations by tagging markers specific to cell subpopulations.  
In Figure B.2, data shows the number of events (corresponding to the number of 
different types of cells) that were collected. For all the 8 dogs (except the dog Alice-pre), 
a total of 10,000 events were collected. Data shows that among all the events, P1 has 
2066 events (20.7%), P2 has 4670 events (46.7%) and P3 has 3251 events (32.5%). For 
the FITC Geo Mean (which corresponds to the expression level of GLUT4, standardized 
to the dogs baseline values), P2 has a higher level of FITC signal compared with P1. The 
number, respectively, are 5 and 10. And P3 does not has a significant FITC signal.  
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Figure B.3 Dot plot for Rossi post-exercise 
 
Figure B.4 Experiment data corresponds to Figure B.3 
Data from Figure B.4 shows that in the Rossi’s post exercise white blood sample, 
among all the 10,000 events, that P1 has 2826 events (28.3%), P2 has 2954 events 
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(29.5%) and P3 has 4186 events (41.9%). For the FITC Geo Mean, P2 has a higher level 
of FITC signal compared with P1. The numbers, respectively, are 5 and 15.  
 
Figure B.5 Dot plot for Rossi 24h-post exercise 
 
Figure B.6 Experiment data corresponds to Figure B.5 
Data from Figure B.6 shows that in THE Rossi 24-post exercise white blood 
sample, among all the 10,000 events, that P1 has 3726 events (37.3%), P2 has 2060 
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events (20.6%) and P3 has 4206 events (42.1%). For the FITC Geo Mean, P2 has a 
stronger signal compare with P1. The numbers, respectively, are 11 and 63.  
Overall, under the 3 different conditions, the white blood samples show these 
following trends in all 8 dogs: 
1. There is an increasing number of events in P1 
2. There is a decreasing number of events in P2 
3. There is no event change in P3 
4. There is an increase in FITC signal in P2, which can indicate the 
increasing expression level of GLUT4 on the membrane of P2 
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Figure B.7 Mean percentage of events of all three populations in pre-exercise 
 
 
Table B.1 Corresponds to Figure B.7 
Population Mean Pre (%) StdDev Pre (+/-) 
P1 18.40 7.50 
P2 47.70 7.20 
P3 33.40 4.10 
  
Figure B.7 shows that in the pre-exercise. Among all the dogs, the P2 has the 
highest percentage of all three populations followed by P3 and then P1. 
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Figure B.8 Mean percentage of events of all three populations in post-exercise 
 
 
Table B.2 Corresponds to Figure B.8 
Population Mean Post (%) StdDev Post (+/-) 
P1 27.70 10.27 
P1 37.20 8.86 
P3 34.50 5.50 
 
Figure B.8 shows the post exercise data. Among all the dogs, the percentages 
events of P1, P2 and P3 do not show a difference. 
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Figure B.9 Mean percentage of events of all three populations in 24h-post exercise 
 
 
Table B.3 Corresponds to Figure B.9 
Population Mean 24h (%) StdDev 24h (+/-) 
P1 38.00 2.10 
P2 23.70 4.90 
P3 38.30 4.40 
 
Figure B.9 shows the 24h-post exercise. Among all the dogs, P1 and P3 have the 
two highest percentages of all the populations, but no difference between these two 
populations. P2 has the lowest percentage of all the populations.  
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Figure B.10 FITC Geo Means in P1’ and P2’ populations in pre-exercise 
 
 
Table B.4 Corresponds to Figure B.10 
Population FITC Geo Mean Pre StdDev Pre (+/-) 
P1’ 5.40 0.70 
P2’ 12.10 4.10 
 
Figure B.10 shows the FITC Geo Mean in P1’ and P2’ in pre-exercise. Among all 
8 dogs, P2’ has a stronger signal of FITC compared with P1’. The P1’ and P2’ are the 
subpopulations of P1 and P2 separately. These subpopulations do not include the FITC 
readings that are smaller than 0 (based on the mathematics rule that Geo Mean can only 
be calculated for the numbers that are bigger than zero). 
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Figure B.11 FITC Geo Means in P1’ and P2’ populations in post-exercise 
 
 
Table B.5 Corresponds to Figure B.11 
Population FITC Geo Mean Post StdDev Post (+/-) 
P1’ 5.80 0.90 
P2’ 15.30 2.90 
 
Figure B.11 shows the FITC Geo Mean in P1’ and P2’ in post-exercise. Among 
all 8 dogs, P2’ has a stronger signal of FITC compared with P1’. In addition, compared 
with the Pre-FITC Geo Mean reading in P2’, Post-FITC Geo Mean in P2’ is higher, and 
there is no change in P1’ FITC Geo Mean in both conditions.
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Figure B12 FITC Geo Means in P1’ and P2’ populations in 24h-post exercise 
 
 
Table B.6 Corresponds to Figure B12 
Population FITC Geo Mean 24h StdDev 24h 
P1’ 9.50 1.30 
P2’ 51.40 14.10 
 
Figure B.12 shows the FITC Geo Mean in P1’ and P2’ in 24h-post exercise data. 
Among all 8 dogs, P2’ has a stronger signal of FITC compared with P1’. Compared to the 
pre-exercise and post-exercise readings, the P2’ has the strongest FITC signal among all 
the three conditions by an increase of about 3 times compared to the pre-exercise and 
about 2 times compared to the post-exercise.
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Conclusion 
From the dot plots collected from Flow Cytometry, our results show cell-
population changes in mononuclear cells of sled dogs. There was an increasing in P1 and 
a decreasing in P2. In order to verify the identity of different mononuclear cells, we will 
use specific antibodies to tag our samples in future experiments.  
From tagging GLUT4, there is an increasing level of GLUT4 throughout the 
experiment, from pre-exercise, post-exercise, to 24h-post exercise in P2. This tendency 
indicates that exercise in sled dogs stimulates the GLUT4 expression on the plasma 
membranes of mononuclear cell. This finding can be very useful for both academic 
research on type II diabetes and insulin resistance, but also the potential clinical 
applications for diagnosis of type II diabetes. The use of blood samples instead of 
biopsies from adipose or muscle tissue, promise to relatively low-invasive and 
inexpensive diagnostic tool for determining GLUT4 levels in individuals. 
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Appendix C Supplementing Data from Sled Dogs Mononuclear cells 
 
Figure C.1 Dot plot for Carpone pre-exercise 
 
Figure C.2 Experiment data corresponds to Figure C.1 
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Figure C.3 Dot plot for Carpone post-exercise 
 
Figure C.4 Experiment data corresponds to Figure C.3 
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Figure C.5 Dot plot for Carpone 24h-post exercose 
 
Figure C.6 Experiment data corresponds to Figure C.5 
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Figure C.7 Dot plot for Subaru pre-exerciser 
 
Figure C.8 Experiment data corresponds to Figure C.7 
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Figure C.9 Dot Plot for Subaru post-exercise 
 
Figure C.10 Experiment data corresponds to Figure C.9 
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Figure C.11 Dot plot for Subaru 24h-post exercise 
 
Figure C.12 Experiment data corresponds to Figure C.11 
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Figure C.13 Dot plot for Curtis pre-exercise 
 
Figure C.14 Experiment data corresponds to Figure C.13 
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Figure C.15 Dot plot for Curtis post-exercise 
 
Figure C.16 Experiment data corresponds to Figure C.15 
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Figure C.17 Dot plot for Curtis 24h-post exercise 
 
Figure C.18 Experiment data corresponds to Figure C.17 
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Figure C.19 Dot plot for Trigger pre-exercise 
 
Figure C.20 Experiment data corresponds to Figure C.19 
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Figure C.21 Dot plot for Trigger post-exercise 
 
Figure C.22 Experiment data corresponds to Figure C.21 
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Figure C.23 Dot plot for Trigger 24h-post exercise 
 
Figure C.24 Experiment data corresponds to Figure C.23 
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Figure C.25 Dot plot for Johnny pre-exercise 
 
Figure C.26 Experiment data corresponds to Figure C.25 
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Figure C.27 Dot plot for Johnny post-exercise 
 
Figure C.28 Experiment data corresponds to Figure C.27 
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Figure C.29 Dot plot for Johnny 24h-post exercise 
 
Figure C.30 Experiment data corresponds to Figure C.29 
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Figure C.31 Dot plot for Floyd pre-exercise 
 
Figure C.32 Experiment data corresponds Figure C.31 
71 
 
Figure C.33 Dot plot for Floyd post-exercise 
 
Figure C.34 Experiment data corresponds to Figure C.33 
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Figure C.35 Dot plot for Floyd 24h-post exercise 
 
Figure C.36 Experiment data corresponds to Figure C.35 
